Circulating tumour-derived predictive biomarkers in oncology

Drug Discovery Today

Volumn 15, Issue 3-4, 2010, Pages 98-101

  Hodgson, Darren R ^a   Wellings, Robert ^a   Orr, Maria C M ^a   McCormack, Rose ^a   Malone, Michael ^a   Board, Ruth E ^b   Cantarini, Mireille V ^a  

^a ASTRAZENECA   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CA 125 ANTIGEN; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; K RAS PROTEIN; PANITUMUMAB; PROSTATE SPECIFIC ANTIGEN; RNA; TRASTUZUMAB; TUMOR MARKER;

BLOOD SAMPLING; BREAST CANCER; CLINICAL PRACTICE; COLORECTAL CANCER; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; HUMAN; LUNG CANCER; MEDICAL DECISION MAKING; ONCOLOGY; PATIENT IDENTIFICATION; PATIENT SELECTION; PROGNOSIS; PROTEIN TARGETING; REVIEW; TUMOR CELL; VALIDATION PROCESS;

COLORECTAL NEOPLASMS; DNA, NEOPLASM; HUMANS; LUNG NEOPLASMS; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; PATIENT SELECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 75549085009     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.12.006     Document Type: Review

References (29)

1. Sørlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 10869-10874
2. Mok T.S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361 (2009) 947-957
3. BMS/Imclone ODAC. Background Document: K-ras Oncology Drugs Advisory Committee (ODAC) (2008). http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4409b1-03-Bristol.p df
4. Hodgson D.R., et al. Biomarkers in oncology drug development. Mol. Oncol. 1 (2009) 24-32
5. Fong P.C., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361 (2009) 123-134
6. Gazdar A.F. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl. 1 (2009) S24-S31
7. Sakai W., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008) 1116-1120
8. Ariga H., et al. Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. Transfusion 41 (2001) 1524-1530
9. Cristofanilli M., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 351 (2004) 781-791
10. de Bono J.S., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14 (2008) 6302-6309
11. Maheswaran S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359 (2008) 366-377
12. Di Leo A., et al. New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann. Oncol. 18 Suppl. 12 (2007) xii8-xii14
13. Nagrath S., et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450 (2007) 1235-1239
14. Hauch S., et al. The clinical significance of circulating tumour cells in breast cancer and colorectal cancer patients. Anticancer Res. 27 (2007) 1337-1341
15. Zieglschmid V., et al. Heterogeneous expression of tumor-associated genes in disseminated breast cancer cells. Anticancer Res. 27 (2007) 1769-1776
16. Shapiro B., et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51 (1983) 2116-2120
17. Koffler D., et al. The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J. Clin. Invest. 52 (1973) 198-204
18. Leon S.A., et al. DNA in synovial fluid and the circulation of patients with arthritis. Arthritis Rheum. 24 (1981) 1142-1150
19. Atamaniuk J., et al. Increased concentrations of cell-free plasma DNA after exhaustive exercise. Clin. Chem. 50 (2004) 1668-1670
20. Lo Y.M., et al. Plasma DNA as a prognostic marker in trauma patients. Clin. Chem. 46 (2000) 319-323
21. Sorenson G.D., et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol. Biomarkers Prev. 3 (1994) 67-71
22. Board R.E., et al. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br. J. Cancer 101 (2009) 1724-1730
23. Bremnes R.M., et al. Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?. Lung Cancer 49 (2005) 1-12
24. Chan K.C.A., and Lo Y.M.D. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br. J. Cancer 96 (2007) 681-685
25. Kimura H., et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br. J. Cancer 97 (2007) 778-784
26. Rosell R., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361 (2009) 958-967
27. Kuang Y., et al. Non-invasive detection of EGFR T790M in gefitinib or erlotinib resistant non small cell lung cancer. Clin. Cancer Res. 15 (2009) 2630
28. Diehl F., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 14 (2008) 985-990
29. Sorenson G.D. Detection of mutated KRAS2 sequences as tumor markers in plasma/serum of patients with gastrointestinal cancer. Clin. Cancer Res. 6 (2000) 2129-2137